Medpace Trails PACS with 27.3x P/E and 28.6 P/B Ratios
Medpace holds a Zacks Rank #3 (Hold) with a forward P/E of 27.34 and PEG ratio of 2.23, compared to PACS Group’s P/E of 17.43 and PEG of 1.16. Medpace’s P/B ratio of 28.58 and Value grade C trail PACS’s P/B of 5.98 and Value grade B.
1. Zacks Rank Comparison
Medpace carries a Zacks Rank #3 (Hold) compared with PACS Group’s #1 (Strong Buy), indicating slower earnings estimate revisions and less analyst optimism for Medpace.
2. Valuation Ratios Detail
Medpace’s forward P/E stands at 27.34, PEG at 2.23 and P/B at 28.58, while PACS shows a forward P/E of 17.43, PEG of 1.16 and P/B of 5.98.
3. Value Grade Outcomes
These valuation metrics result in a Value grade of C for Medpace versus B for PACS, suggesting PACS offers more attractive value characteristics for investors focused on discounted stock prices.
Related News
VBCJ
Vanguard BondBuilder Corporate ETFs amass $242M, boosting segment to $70B
VBCJ•
NBTX
Nanobiotix Halts Trading to Finalize €75 M Follow-On Offering Pricing
NBTX•
UXIN
Uxin to Launch 5,000-Vehicle Chongqing Superstore in 2026 Expansion Drive
UXIN•
NVDA
Nvidia Projects $20 Billion in CPU Sales Within $200 Billion Market
NVDA•
AMZN
Amazon MGM Invests $75M in Melania Documentary Despite Political Scrutiny
AMZN•
Sources
F